Expression, purification, and breast cancer cell inhibiting effect of recombinant human lactoferrin C-lobe

References

• Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int. J. Antimicrob. Agents. 2009;33:e301–e308.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Q, Ou Y, Han Z, et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch. Pharm. Res. 2011;34:987–995.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Sato R, Kobayashi S, et al. The antiproliferative effect of bovine lactoferrin on canine mammary gland tumor cells. J. Vet. Med. Sci. 2008;70:443–448.
   PubMed Web of Science ®Google Scholar
• Kuhara T, Yamauchi K, Tamura Y, et al. Oral administration of lactoferrin increases nk cell activity in mice via increased production of IL-18 and type I IFN in the small intestine. J. Interferon. Cytokine Res. 2006;26:489–499.
   PubMed Web of Science ®Google Scholar
• Kuhara T, Iigo M, Itoh T, et al. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer. 2000;38:192–199.
   PubMed Web of Science ®Google Scholar
• Chandra Mohan KV, Kumaraguruparan R, Prathiba D, et al. Modulation of xenobiotic-metabolizing enzymes and redox status during chemoprevention of hamster buccal carcinogenesis by bovine lactoferrin. Nutrition. 2006;22:940–946.
   PubMed Web of Science ®Google Scholar
• Shimamura M, Yamamoto Y, Ashino H, et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer. 2004;111:111–116.
   PubMed Web of Science ®Google Scholar
• Lee SH, Park SW, Pyo CW, et al. Requirement of the JNK-associated Bcl-2 pathway for human lactoferrin-induced apoptosis in the Jurkat leukemia T cell line. Biochimie. 2009;91:102–108.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Monitto CL, Minhas KM, et al. Lactoferrin down-regulates G1 cyclin-dependent kinases during growth arrest of head and neck cancer cells. Clin. Cancer Res. 2004;10:8683–8686.
   PubMed Web of Science ®Google Scholar
• Damiens E, El Yazidi I, Mazurier J, et al. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J. Cell Biochem. 1999;74:486–498.
   PubMed Web of Science ®Google Scholar
• Vogel HJ. Lactoferrin, a bird’s eye view. Biochem. Cell Biol. 2012;90:233–244.
   PubMed Web of Science ®Google Scholar
• Sheth B, Stowell KM, Day CL, et al. Cloning and expression of the C-terminal lobe of human lactoferrin. Adv. Exp. Med. Biol. 1994;357:259–263.
   PubMedGoogle Scholar
• Lizzi AR, Carnicelli V, Clarkson MM, et al. Lactoferrin derived peptides: mechanisms of action and their perspectives as antimicrobial and antitumoral agents. Mini. Rev. Med. Chem. 2009;9:687–695.
   PubMed Web of Science ®Google Scholar
• Puddu P, Latorre D, Valenti P, et al. Immunoregulatory role of lactoferrin-lipopolysaccharide interactions. BioMetals. 2010;23:387–397.
   PubMed Web of Science ®Google Scholar
• Sinha M, Kaushik S, Kaur P, et al. Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. Int. J. Pept. 2013;2013: 390230.
   PubMedGoogle Scholar
• Takayama Y, Mizumachi K, Takezawa T. The bovine lactoferrin region responsible for promoting the collagen gel contractile activity of human fibroblasts. Biochem. Biophys. Res. Commun. 2002;299:813–817.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Kim WS, Ito T, et al. Growth promotion and cell binding ability of bovine lactoferrin to Bifidobacterium longum. Anaerobe. 2009;15:133–137.
   PubMed Web of Science ®Google Scholar
• Mir R, Singh N, Vikram G, et al. The structural basis for the prevention of nonsteroidal antiinflammatory drug-induced gastrointestinal tract damage by the c-lobe of bovine colostrum lactoferrin. Biophys. J. 2009;97:3178–3186.
   PubMed Web of Science ®Google Scholar
• Mir R, Kumar RP, Singh N, et al. Specific interactions of C-terminal half (C-lobe) of lactoferrin protein with edible sugars: binding and structural studies with implications on diabetes. Int. J. Biol. Macromol. 2010;47:50–59.
   PubMed Web of Science ®Google Scholar
• Ashby B, Garrett Q, Willcox M. Bovine lactoferrin structures promoting corneal epithelial wound healing in vitro. Invest. Ophthalmol. Vis. Sci. 2011;52:2719–2726.
   PubMed Web of Science ®Google Scholar
• Sharma S, Sinha M, Kaushik S, et al. C-lobe of lactoferrin: the whole story of the half-molecule. Biochem. Res. Int. 2013;2013: 271641.
   PubMedGoogle Scholar
• Legrand D, Elass E, Carpentier M, et al. Interactions of lactoferrin with cells involved in immune function. Biochem. Cell Biol. 2006;84:282–290.
   PubMed Web of Science ®Google Scholar
• Artym J. Antitumor and chemopreventive activity of lactoferrin. Postepy. Hig. Med. Dosw. (Online). 2006;60:352–369.
   PubMedGoogle Scholar
• Zhang Y, Lima CF, Rodrigues LR. Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy. Nutr. Rev. 2014;72:763–773.
   PubMed Web of Science ®Google Scholar
• Elass-Rochard E, Roseanu A, Legrand D, et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem. J. 1995;312:839–845.
   PubMed Web of Science ®Google Scholar
• Van Berkel PH, Geerts ME, Van Veen HA, et al. N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 1997;328:145–151.
   PubMed Web of Science ®Google Scholar
• Andersen JH, Jenssen H, Sandvik K, et al. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparan sulphate at the cell surface. J. Med. Virol. 2004;74:262–271.
   PubMed Web of Science ®Google Scholar
• Ziere GJ, Kruijt JK, Bijsterbosch MK, et al. Recognition of lactoferrin and aminopeptidase M-modified lactoferrin by the liver: involvement of proteoglycans and the remnant receptor. Biochem. J. 1996;313:289–295.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zeng Z, Zhang W, Wu M, et al. Lactotransferrin: a candidate tumor suppressor-deficient expression in human nasopharyngeal carcinoma and inhibition of npc cell proliferation by modulating the mitogen-activated protein kinase pathway. Int. J. Cancer. 2008;123:2065–2072.
   PubMed Web of Science ®Google Scholar
• McKeown ST, Lundy FT, Nelson J, et al. The cytotoxic effects of human neutrophil peptide-1 (HNP1) and lactoferrin on oral squamous cell carcinoma (OSCC) in vitro. Oral Oncol. 2006;42:685–690.
   PubMed Web of Science ®Google Scholar